Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Felbamate-induced headache

A B Ettinger1, L Jandorf, A Berdia

  • 1Department of Neurology, State University of New York at Stony Brook 11794-8121, USA.

Epilepsia
|May 1, 1996
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Remotely-delivered cognitive remediation in multiple sclerosis (MS): protocol and results from a pilot study.

Multiple sclerosis journal - experimental, translational and clinical·2017
Same author

Longitudinal evaluation of cognitive functioning in pediatric multiple sclerosis: report from the US Pediatric Multiple Sclerosis Network.

Multiple sclerosis (Houndmills, Basingstoke, England)·2014
Same author

Social cognition in pediatric-onset multiple sclerosis (MS).

Multiple sclerosis (Houndmills, Basingstoke, England)·2014
Same author

Copy number variation in pediatric multiple sclerosis.

Multiple sclerosis (Houndmills, Basingstoke, England)·2012
Same author

Ethnic, racial and cultural identity and perceived benefits and barriers related to genetic testing for breast cancer among at-risk women of African descent in New York City.

Public health genomics·2011
Same author

Multicenter randomized clinical trial of donepezil for memory impairment in multiple sclerosis.

Neurology·2011
Same journal

Raising resilience: A parenting intervention for families affected by childhood epilepsy.

Epilepsia·2026
Same journal

Epileptogenic lesions in the Australian epilepsy project: A harmonized 3-T magnetic resonance imaging protocol and its diagnostic yield.

Epilepsia·2026
Same journal

Responsible use of artificial intelligence in peer-reviewed publications in epilepsy.

Epilepsia·2026
Same journal

Altered autonomic balance drives the increase in cardiac output and arterial pressure during convulsive seizures in nonanesthetized sheep.

Epilepsia·2026
Same journal

Diagnostic yield and copy number variants findings in 219 adult patients with developmental and epileptic encephalopathy.

Epilepsia·2026
Same journal

Prolonged fenfluramine use in open-label studies of Dravet or Lennox-Gastaut syndromes: Long-term safety, tolerability, patient global functioning, and considerations for interpreting effectiveness.

Epilepsia·2026
See all related articles

Headaches are a common side effect for epilepsy patients taking felbamate (FBM). Reducing the FBM dose often relieves these headaches, which typically occur early in treatment.

Area of Science:

  • Neurology
  • Pharmacology

Background:

  • Epilepsy management often involves multiple antiepileptic drugs.
  • Felbamate (FBM) is an antiepileptic medication with a known side effect profile.

Purpose of the Study:

  • To prospectively investigate the incidence and characteristics of drug-induced headaches in epileptic patients treated with felbamate (FBM).

Main Methods:

  • Prospective investigation of 60 epileptic patients receiving felbamate.
  • Data collection on headache occurrence, characteristics, and response to interventions.

Main Results:

  • 33% of patients experienced headaches (HA) while on felbamate.
  • Headaches were typically moderate to severe, frequent, and dose-related.
  • Dose reduction of felbamate relieved headaches in 62% of cases.

Related Experiment Videos

  • Headache onset occurred at a mean of 19 days after FBM initiation.
  • Other side effects included insomnia, gastrointestinal issues, and agitation.

    • Conclusions:

    • Headache is a common, dose-related complication of felbamate treatment in epilepsy.
    • Headaches often occur early in treatment and can be managed by reducing the felbamate dose.
    • Felbamate discontinuation was primarily due to other risks (anemia, hepatitis) rather than headaches.